JP2011509920A - 虚血又は再灌流事象によって引き起こされる心臓の障害又は間接的な後遺症の治療又は予防のための尿酸オキシダーゼの使用 - Google Patents

虚血又は再灌流事象によって引き起こされる心臓の障害又は間接的な後遺症の治療又は予防のための尿酸オキシダーゼの使用 Download PDF

Info

Publication number
JP2011509920A
JP2011509920A JP2010523299A JP2010523299A JP2011509920A JP 2011509920 A JP2011509920 A JP 2011509920A JP 2010523299 A JP2010523299 A JP 2010523299A JP 2010523299 A JP2010523299 A JP 2010523299A JP 2011509920 A JP2011509920 A JP 2011509920A
Authority
JP
Japan
Prior art keywords
treatment
urate oxidase
prevention
ischemia
rasburicase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010523299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509920A5 (https=
Inventor
ヴォルフガング・リンツ
マティーアス・シェーファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2011509920A publication Critical patent/JP2011509920A/ja
Publication of JP2011509920A5 publication Critical patent/JP2011509920A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2010523299A 2007-09-05 2008-08-20 虚血又は再灌流事象によって引き起こされる心臓の障害又は間接的な後遺症の治療又は予防のための尿酸オキシダーゼの使用 Pending JP2011509920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291072 2007-09-05
US1524007P 2007-12-20 2007-12-20
PCT/EP2008/006858 WO2009030373A1 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events

Publications (2)

Publication Number Publication Date
JP2011509920A true JP2011509920A (ja) 2011-03-31
JP2011509920A5 JP2011509920A5 (https=) 2011-10-06

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010523299A Pending JP2011509920A (ja) 2007-09-05 2008-08-20 虚血又は再灌流事象によって引き起こされる心臓の障害又は間接的な後遺症の治療又は予防のための尿酸オキシダーゼの使用

Country Status (22)

Country Link
US (1) US20100266567A1 (https=)
EP (1) EP2197550A1 (https=)
JP (1) JP2011509920A (https=)
KR (1) KR20100053609A (https=)
CN (1) CN101801460A (https=)
AR (1) AR068360A1 (https=)
AU (1) AU2008295145B2 (https=)
BR (1) BRPI0816406A2 (https=)
CA (1) CA2697929A1 (https=)
CL (1) CL2008002623A1 (https=)
CO (1) CO6260090A2 (https=)
IL (1) IL204259A (https=)
MA (1) MA31624B1 (https=)
MX (1) MX2010001976A (https=)
MY (1) MY183770A (https=)
NZ (1) NZ583635A (https=)
PA (1) PA8794801A1 (https=)
PE (1) PE20090642A1 (https=)
TW (1) TW200927929A (https=)
UY (1) UY31320A1 (https=)
WO (1) WO2009030373A1 (https=)
ZA (1) ZA201000774B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026118A2 (en) * 2002-09-20 2004-04-01 Oregon Health & Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
US20050232902A1 (en) * 2004-04-17 2005-10-20 Theodoros Kofidis Injectable bioartificial tissue matrix
JP2007522806A (ja) * 2004-02-09 2007-08-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド アルブミン融合蛋白質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
JP2004517804A (ja) * 2000-06-28 2004-06-17 メルク・アンド・カンパニー・インコーポレーテッド 心臓血管病の治療法
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026118A2 (en) * 2002-09-20 2004-04-01 Oregon Health & Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
JP2007522806A (ja) * 2004-02-09 2007-08-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド アルブミン融合蛋白質
US20050232902A1 (en) * 2004-04-17 2005-10-20 Theodoros Kofidis Injectable bioartificial tissue matrix

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JPN5010016266; ＷＡＴＡＮＡＢＥ　Ｓ: 'ＲＥＤＵＣＩＮＧ　ＵＲＩＣ　ＡＣＩＤ　ＡＳ　Ａ　ＭＥＡＮＳ　ＴＯ　ＰＲＥＶＥＮＴ　ＣＡＲＤＩＯＶＡＳＣＵＬＡＲ　ＡＮＤ　ＲＥＮＡＬ　ＤＩＳＥＡＳＥ' ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＴＨＥＲＡＰＥＵＴＩＣ　ＰＡＴＥＮＴＳ Ｖ１２　Ｎ２, 2002, Ｐ１９３-１９９, ＡＳＨＬＥＹ　ＰＵＢＬＩＣＡＴＩＯＮＳ　ＬＴＤ． *
JPN6013017469; Ｓｙｌｖｉｅ　Ｒｏｚｅｎｂｅｒｇ，　ｅｔ　ａｌ．: 'Ｕｒａｔｅ-ｏｘｉｄａｓｅ　ｆｏｒ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｔｏｐｈａｃｅｏｕｓ　ｇｏｕｔ　ｉｎ　ｈｅａｒｔ　ｔｒａｎｓｐｌａｎｔ　ｒｅｃｉｐｉｅｎｔｓ' Ｒｅｖｕｅ　ｄｕ　ｒｈｕｍａｔｉｓｍｅ ６２（５）, 1995, ３９２-３９４ *
JPN6013017472; ＦＡＮＧ，Ｊ．　ｅｔ　ａｌ: 'Ｓｅｒｕｍ　ｕｒｉｃ　ａｃｉｄ　ａｎｄ　ｃａｒｄｉｏｖａｓｃｕｌａｒ　ｍｏｒｔａｌｉｔｙ　ｔｈｅ　ＮＨＡＮＥＳ　Ｉ　ｅｐｉｄｅｍｉｏｌｏｇｉｃ　ｆｏｌｌｏｗ-ｕｐ　ｓｔｕｄｙ，　１９７１-１９９２．' ＪＡＭＡ Ｖｏｌ．２８３，　Ｎｏ．１８, 2000, ｐ．２４０４-１０ *
JPN6014009234; Ｎｉｃｏｌｅ　Ａ．　Ｗｅｉｍｅｒｔ，　ｅｔ　ａｌ．: 'Ａｌｌｏｐｕｒｉｎｏｌ　ａｓ　ａ　ｃａｒｄｉｏｐｒｏｔｅｃｔａｎｔ　ｄｕｒｉｎｇ　ｃｏｒｏｎａｒｙ　ａｒｔｅｒｙ　ｂｙｐａｓｓ　ｇｒａｆｔ　ｓｕｒｇｅｒｙ' Ａｎｎ　Ｐｈａｒｍａｃｏｔｈｅｒ ３７（１１）, 2003, １７０８-１１ *
JPN6014009236; 石河利一郎ら: '虚血-再潅流によるモルモット摘出心臓の尿酸産生とキサンチン酸化酵素阻害薬の影響' 臨床薬理 ２１（１）, 1990, ２５１-２ *
JPN6014009238; ＭＯＲＩＹＡＭＡ　Ｙ，　ｅｔ　ａｌ．: 'Ｅｆｆｅｃｔ　ｏｆ　ｆｒｅｅ　ｒａｄｉｃａｌ　ｓｃａｖｅｎｇｅｒｓ　ｆｏｒ　ｃａｎｉｎｅ　ｍｙｏｃａｒｄｉａｌ　ｐｒｏｔｅｃｔｉｏｎ　ａｆｔｅｒ　ｐｒｏｌｏｎｇｅｄ　ｈｙｐｏｔｈｅｒｍｉｃ　ｓｔｏｒａ' 低温医学 １４（１）, 1988, ２６-３１ *
JPN6014009240; 中村好男ら: '高血圧と高尿酸血症　動脈硬化の成因とフリーラジカル・高尿酸血症' 血圧 ７（１２）, 2000, １１７７-８１ *
JPN6014009242; Ｓｕｓａｎ　Ｌ．　ＴＨＯＭＰＳＯＮ-ＧＯＲＭＡＮ，　ｅｔ　ａｌ．: 'Ｅｖａｌｕａｔｉｏｎ　ｏｆ　ｔｈｅ　ｒｏｌｅ　ｏｆ　ｘａｎｔｈｉｎｅ　ｏｘｉｄａｓｅ　ｉｎ　ｍｙｏｃａｒｄｉａｌ　ｒｅｐｅｒｆｕｓｉｏｎ　ｉｎｊｕｒｙ' Ｊ　Ｂｉｏｌ　Ｃｈｅｍ ２６５（１２）, 1990, ６６５６-６３ *
JPN6014009244; Ｍｏｒｒｉｓ　Ｋａｒｍａｚｙｎ: 'Ａ　ｄｉｒｅｃｔ　ｐｒｏｔｅｃｔｉｖｅ　ｅｆｆｅｃｔ　ｏｆ　ｓｕｌｐｈｉｎｐｙｒａｚｏｎｅ　ｏｎ　ｉｓｃｈａｅｍｉｃ　ａｎｄ　ｒｅｐｅｒｆｕｓｅｄ　ｒａｔ　ｈｅａｒｔｓ' Ｂｒ　Ｊ　Ｐｈａｒｍａｃｏｌ ８３（１）, 1984, ２２１-６ *
JPN6014009246; Ａｌｄｅｒｍａｎ　Ｍｉｃｈａｅｌ，　ｅｔ　ａｌ．: 'Ｕｒｉｃ　ａｃｉｄ：　ｒｏｌｅ　ｉｎ　ｃａｒｄｉｏｖａｓｃｕｌａｒ　ｄｉｓｅａｓｅ　ａｎｄ　ｅｆｆｅｃｔｓ　ｏｆ　ｌｏｓａｒｔａｎ' Ｃｕｒｒ　Ｍｅｄ　Ｒｅｓ　Ｏｐｉｎ ２０（３）, 2004, ３６９-７９ *
JPN6014009248; Ｂａｋｅｒ，　Ｊｏｓｈｕａ　Ｆ．，　ｅｔ　ａｌ．: 'Ｓｅｒｕｍ　ｕｒｉｃ　ａｃｉｄ　ａｎｄ　ｃａｒｄｉｏｖａｓｃｕｌａｒ　ｄｉｓｅａｓｅ：　ｒｅｃｅｎｔ　ｄｅｖｅｌｏｐｍｅｎｔｓ，　ａｎｄ　ｗｈｅｒｅ　ｄｏ　ｔｈｅｙ　ｌｅａｖｅ　ｕｓ？' Ａｍ　Ｊ　Ｍｅｄ １１８（８）, 2005, ８１６-２６ *
JPN6014009251; Ｊｅｓｓｅ　Ｄａｗｓｏｎ，　ｅｔ　ａｌ．: 'Ｕｒｉｃ　ａｃｉｄ　ａｎｄ　ｘａｎｔｈｉｎｅ　ｏｘｉｄａｓｅ：　ｆｕｔｕｒｅ　ｔｈｅｒａｐｅｕｔｉｃ　ｔａｒｇｅｔｓ　ｉｎ　ｔｈｅ　ｐｒｅｖｅｎｔｉｏｎ　ｏｆ　ｃａｒｄｉｏｖａｓｃｕｌａｒ　ｄｉｓｅａ' Ｂｒ　Ｊ　Ｃｌｉｎ　Ｐｈａｒｍａｃｏｌ ６２（６）, 2006, ６３３-４４ *

Also Published As

Publication number Publication date
TW200927929A (en) 2009-07-01
EP2197550A1 (en) 2010-06-23
NZ583635A (en) 2011-06-30
MA31624B1 (fr) 2010-08-02
MY183770A (en) 2021-03-12
CA2697929A1 (en) 2009-03-12
WO2009030373A1 (en) 2009-03-12
MX2010001976A (es) 2010-03-10
PE20090642A1 (es) 2009-06-18
UY31320A1 (es) 2009-04-30
AU2008295145B2 (en) 2013-12-05
RU2010112867A (ru) 2011-10-10
ZA201000774B (en) 2011-04-28
PA8794801A1 (es) 2009-04-23
CO6260090A2 (es) 2011-03-22
CN101801460A (zh) 2010-08-11
KR20100053609A (ko) 2010-05-20
US20100266567A1 (en) 2010-10-21
BRPI0816406A2 (pt) 2017-05-16
CL2008002623A1 (es) 2009-01-16
AR068360A1 (es) 2009-11-11
AU2008295145A1 (en) 2009-03-12
IL204259A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
US8852582B2 (en) Compositions comprising glutathione reductase and oxidized glutathione
US6534501B2 (en) Allosteric inhibitors of pyruvate kinase
JP4842247B2 (ja) マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた代謝性疾患の治療法
US6617337B1 (en) Use of nitroxides for the treatment of essential hypertension
KR102347721B1 (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
Zou et al. Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction
Lai et al. Fullerene derivative attenuates ischemia-reperfusion-induced lung injury
US9585847B2 (en) Small molecule xanthine oxidase inhibitors and methods of use
JP2011520808A (ja) 正常細胞の保護
Ferder et al. Effects of renin–angiotensin system blockade in the aging kidney
CN116234563A (zh) 抗致病治疗方法
JP2001505209A (ja) ヒドロキシグアニジン類の使用
Pędzińska-Betiuk et al. Chronic cannabidiol treatment reduces the carbachol-induced coronary constriction and left ventricular cardiomyocyte width of the isolated hypertensive rat heart
Cantrell et al. Ferrostatin-1 specifically targets mitochondrial iron-sulfur clusters and aconitase to improve cardiac function in Sirtuin 3 cardiomyocyte knockout mice
JP2011509920A (ja) 虚血又は再灌流事象によって引き起こされる心臓の障害又は間接的な後遺症の治療又は予防のための尿酸オキシダーゼの使用
EP3313414A1 (fr) Kit destiné au traitement du sepsis et/ou de toute hyper-inflammation généralisée (sirs) ou cellulaire dommageable
US20210317070A1 (en) Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
US20140255382A1 (en) Solid composition containing a hypothiocyanite salt
RU2482187C2 (ru) Применение расбуриказы для лечения или профилактики расстройств или косвенных осложнений на сердце, вызванных приступами ишемии или реперфузией
KR100879253B1 (ko) 에이디피-라이보실 사이클레이즈 억제제를 이용한 고혈압 및 당뇨병성 신증의 치료제
HK1143771A (en) Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
KR20220015428A (ko) 단백질 클로토(Klotho)의 생산을 활성화할 수 있는 시트레이트 및 카르니틴을 포함하는 조성물
EP4582094A1 (en) Ischemia-reperfusion injury inhibitor
Visokinskas et al. Use of Mildronate in geriatric patients with congestive heart failure
Tao et al. β-Nicotinamide Mononucleotide protects against endotoxemia-induced myocardial injury through Sirt5-dependent desuccinylation of succinate dehydrogenase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805